Registry collecting real-world data on lung cancer testing and treatment
Collects real-world data on molecular tumour testing in adults with advanced lung cancer.
Plain-language title generated from the registry record
Registry title: EMPATHY NSCLC: European Registry for Plasma-Based Molecular Profiling in Advanced NSCLC Patients
Key facts
- Where
- Madrid, SpainSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The registry is looking for adults with advanced lung cancer (non-small cell type) who have not yet had treatment for this advanced disease and plan to start first treatment.
- Age
- At least 18 years
- Sex
- All sexes can join
- Disease stage
- Non-small cell lung cancer that is locally advanced or has spread, cannot be removed by surgery, stage IIIB/C or IV
- Earlier treatment
- No earlier treatment for this advanced disease; first treatment is planned
Main reasons for not taking part
- Another known cancer (other than the lung cancer, and early-stage non-invasive cervical cancer) in the 5 years before joining, except skin cancers
- ECOG performance status above 2
- Cannot sign the informed consent
Read by machine on 12 November 2026.
Where in Spain
- General Universitario Gregorio MarañonMadrid, SpainContact: Dr. Christian Meisel, MD PhDNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Hedera Dx SA
- Trial code
- NCT07096258
- Record updated
- 31 July 2025
- Original description
The goal of this registry is to capture real-world data from plasma- and tissue-based molecular profiling, treatments, outcomes and patient-reported outcomes from patients with advanced or metastatic non-small cell lung cancer (NSCLC). The main objective of the study is to better understand the real-world clinical practice of the use and utility of molecular tumour profiling, the choice of treatment, and the outcome after such molecular profiling and treatment.Read full original descriptionShow less
A Patient Registry Collecting the Clinical and Molecular Profiling Data of Patients With Locally Advanced and/or Metastatic, Unresectable, Stages IIIB/C or IV Non-small Cell Lung Cancer (NSCLC), Who Have Not Previously Been Treated for This Advanced Disease and Are Therefore Considered as Patients Receiving First-line Therapy.
The goal of this registry is to capture real-world data from plasma- and tissue-based molecular profiling, treatments, outcomes and patient-reported outcomes from patients with advanced or metastatic non-small cell lung cancer (NSCLC). The main objective of the study is to better understand the real-world clinical practice of the use and utility of molecular tumour profiling, the choice of treatment, and the outcome after such molecular profiling and treatment.
Inclusion: Locally advanced or metastatic, unresectable NSCLC, stages IIIB/C or IV, who have not previously been treated for this advanced disease; Intention-to-initiate first-line tumour therapy for this advanced disease; Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2; At least 18 years of age on the day of signing informed consent, and capable of signing informed consent.
Exclusion: Any known non-cutaneous malignancy (except for this NSCLC and early-stage non-invasive cervical cancer) that has occurred within 5 years prior to enrolment.